Big Pharma cashes in on HGH abuse

by David B. Caruso

An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies.

The crackdown, which began in 2006, reduced the illegal flow of unregulated supplies from China, India and Mexico. But since then, Big Pharma has been satisfying the steady desires of U.S. users and abusers, including many who take the drug in the false hope of delaying aging.

An AP analysis of pharmaceutical company data shows that from 2005 to 2011, inflation-adjusted sales of HGH were up 69 percent. During the same period, sales of the average prescription drug rose 12 percent.

Under U.S. law, HGH can only be dispensed for very rare conditions.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Data firm sees 2011 drug sales rising 5-7 percent

Oct 07, 2010

(AP) -- Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm ...

Global spending on drugs to slow through 2016

Jul 12, 2012

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

9 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.